Management of relapsing–remitting multiple sclerosis in Latin America: Practical recommendations for treatment optimization

[1]  C. Eccleston,et al.  Systematic review and meta-analysis of psychological therapies for children with chronic pain. , 2014, Journal of pediatric psychology.

[2]  L. Kappos,et al.  Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial , 2014, Multiple sclerosis.

[3]  M. Mura,et al.  Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up , 2014, Neurological Sciences.

[4]  G. Capkun,et al.  Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis , 2013, Current medical research and opinion.

[5]  A. Bergmann,et al.  Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort , 2013, Journal of Neurology.

[6]  P. Vermersch,et al.  l-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients , 2013, Neurology.

[7]  M. Garcia-Montojo,et al.  Anti-JCV Antibodies Detection and JCV DNA Levels in PBMC, Serum and Urine in a Cohort of Spanish Multiple Sclerosis Patients Treated with Natalizumab , 2013, Journal of Neuroimmune Pharmacology.

[8]  Craig S. Miller,et al.  JC virus antibody status underestimates infection rates , 2013, Annals of neurology.

[9]  J. Correale,et al.  The epidemiology of multiple sclerosis in Latin America and the Caribbean: a systematic review , 2013, Multiple sclerosis.

[10]  J. DeLuca,et al.  Treatment of cognitive impairment in multiple sclerosis: position paper , 2013, Journal of Neurology.

[11]  Douglas L Arnold,et al.  Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations , 2013, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[12]  P. Gustafson,et al.  Interferon beta and long-term disability in multiple sclerosis. , 2013, JAMA neurology.

[13]  M. Krumbholz,et al.  Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis , 2013, Journal of Neurology.

[14]  B Stubinski,et al.  Scoring treatment response in patients with relapsing multiple sclerosis , 2013, Multiple sclerosis.

[15]  J. Anaya,et al.  Prevalence and clinical features of multiple sclerosis in Latin America , 2013, Clinical Neurology and Neurosurgery.

[16]  B. Healy,et al.  Assessment of Definitions of Sustained Disease Progression in Relapsing-Remitting Multiple Sclerosis , 2013, Multiple sclerosis international.

[17]  L. Kappos,et al.  Teriflunomide Efficacy and Safety in Patients with Relapsing Multiple Sclerosis: Results from TOWER, a Second, Pivotal, Phase 3 Placebo-Controlled Study (S01.004) , 2013 .

[18]  F. Cendes,et al.  Prognostic indicators for long-term disability in multiple sclerosis patients , 2013, Journal of the Neurological Sciences.

[19]  I. Boström,et al.  Sex ratio of multiple sclerosis in the National Swedish MS Register (SMSreg) , 2013, Multiple sclerosis.

[20]  E. Cristiano,et al.  Documento de consenso de LACTRIMS para el tratamiento farmacológico de la esclerosis múltiple y sus variantes clínicas , 2012 .

[21]  T. Holmøy,et al.  Vitamin D supplementation and monitoring in multiple sclerosis: who, when and wherefore , 2012, Acta neurologica Scandinavica. Supplementum.

[22]  L. Thuler,et al.  African Ancestry Is a Predictor Factor to Secondary Progression in Clinical Course of Multiple Sclerosis , 2012, ISRN neurology.

[23]  Paula Agurto,et al.  [Neuropsychological assessment of patients with relapsing remitting multiple sclerosis prior to the use of immunomodulatory drugs]. , 2012, Revista medica de Chile.

[24]  F. Malfetano,et al.  Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort. , 2012, Arquivos de neuro-psiquiatria.

[25]  A. Ochoa,et al.  Absence of Multiple Sclerosis and Demyelinating Diseases among Lacandonians, a Pure Amerindian Ethnic Group in Mexico , 2012, Multiple sclerosis international.

[26]  C. McCulloch,et al.  Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis , 2012, Annals of neurology.

[27]  Meena Subramanyam,et al.  Risk of natalizumab-associated progressive multifocal leukoencephalopathy. , 2012, The New England journal of medicine.

[28]  J. Hillert,et al.  Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice , 2012, Multiple sclerosis.

[29]  A. Lutterotti,et al.  Persistency of neutralizing antibodies depends on titer and interferon-beta preparation , 2012, Multiple sclerosis.

[30]  F. Blanc,et al.  Recommendations for the management of multiple sclerosis relapses. , 2012, Revue neurologique.

[31]  Jeffrey A. Cohen,et al.  Fingolimod Treatment Increases the Proportion of Patients Who Are Free from Disease Activity in Multiple Sclerosis Compared to IFN-b1a: Results from a Phase 3, Active-Controlled Study (TRANSFORMS) (PD5.006) , 2012 .

[32]  J. Nicholas,et al.  Response to disease modifying therapies in African Americans with multiple sclerosis. , 2012, Ethnicity & disease.

[33]  G. Nagels,et al.  Sunlight exposure and sun sensitivity associated with disability progression in multiple sclerosis , 2012, Multiple sclerosis.

[34]  O. Fernández-Fernández,et al.  Normalización y validación de la batería neuropsicológica breve como test neuropsicológico de referencia en la esclerosis múltiple , 2012 .

[35]  M. Filippi,et al.  A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[36]  S. Mellgren,et al.  Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial , 2012, Multiple sclerosis.

[37]  R. Kinkel,et al.  Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. , 2012, Archives of neurology.

[38]  X. Montalban,et al.  Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab , 2012, Multiple sclerosis.

[39]  H. Tremlett,et al.  Long-term persistence with the immunomodulatory drugs for multiple sclerosis: a retrospective database study. , 2012, Clinical therapeutics.

[40]  M. Lana-Peixoto,et al.  The prevalence of multiple sclerosis in Belo Horizonte, Brazil. , 2012, Arquivos de neuro-psiquiatria.

[41]  J. Correale,et al.  Vitamin D-mediated immune regulation in Multiple Sclerosis , 2011, Journal of the Neurological Sciences.

[42]  Stephen M. Rao,et al.  Epidemiological characteristics of cognitive impairment of multiple sclerosis patients in a Latin American country , 2011, Journal of clinical and experimental neuropsychology.

[43]  M. Freedman.  Multiple sclerosis therapeutic strategies: Use second-line agents as first-line agents when time is of the essence. , 2011, Neurology. Clinical practice.

[44]  Y. Fragoso,et al.  Assessment of cognition using the Rao's Brief Repeatable Battery of Neuropsychological Tests on a group of Brazilian patients with multiple sclerosis. , 2011, Arquivos de neuro-psiquiatria.

[45]  D. Goodin,et al.  Establishing Long-Term Efficacy in Chronic Disease: Use of Recursive Partitioning and Propensity Score Adjustment to Estimate Outcome in MS , 2011, PloS one.

[46]  K. Rammohan,et al.  WriteClick: Editor’s Choice DISEASE ACTIVITY RETURN DURING NATALIZUMAB TREATMENT INTERRUPTION IN PATIENTS WITH MULTIPLE SCLEROSIS , 2011 .

[47]  J. Correale,et al.  Optimizing outcomes in multiple sclerosis: consensus guidelines for the diagnosis and treatment of multiple sclerosis in Latin America , 2011, Therapeutic advances in neurological disorders.

[48]  M. Stein,et al.  A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis , 2011, Neurology.

[49]  Christian Confavreux,et al.  Randomized trial of oral teriflunomide for relapsing multiple sclerosis. , 2011, The New England journal of medicine.

[50]  M Daumer,et al.  Age and disability accumulation in multiple sclerosis , 2011, Neurology.

[51]  E. Leray,et al.  Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients , 2011, Journal of the Neurological Sciences.

[52]  P. Cabre,et al.  Response to Interferon-Beta Treatment in Afro-Caribbeans with Multiple Sclerosis , 2011, Multiple sclerosis international.

[53]  C. Tornatore,et al.  Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data. , 2011, Archives of neurology.

[54]  R. Kinkel,et al.  Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. , 2011, Archives of neurology.

[55]  K. Dear,et al.  Sun exposure and vitamin D are independent risk factors for CNS demyelination , 2011, Neurology.

[56]  E. Vittinghoff,et al.  Switching Multiple Sclerosis Patients with Breakthrough Disease to Second-Line Therapy , 2011, PloS one.

[57]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[58]  D. Bates.  Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials , 2011, Neurology.

[59]  L. Kappos,et al.  Impact of exposure to interferon beta-1a on outcomes in patients with relapsing–remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study , 2011, Therapeutic advances in neurological disorders.

[60]  C. Otte,et al.  Correlates of cognitive dysfunction in multiple sclerosis , 2010, Brain, Behavior, and Immunity.

[61]  F. Barkhof,et al.  Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[62]  K. Simon,et al.  Anti‐JC virus antibodies: Implications for PML Risk Stratification , 2010, Annals of neurology.

[63]  T. Dwyer,et al.  Higher 25‐hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis , 2010, Annals of neurology.

[64]  C. Granger,et al.  Rapid disease course in African Americans with multiple sclerosis , 2010, Neurology.

[65]  X. Montalban,et al.  Documento de consenso de la Sociedad Española de Neurología sobre el uso de medicamentos en esclerosis múltiple: escalado terapéutico , 2010 .

[66]  D. Goodin,et al.  Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[67]  George C. Ebers,et al.  The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability , 2010, Brain : a journal of neurology.

[68]  G. Ebers,et al.  Multiple sclerosis, vitamin D, and HLA-DRB1*15 , 2010, Neurology.

[69]  D. Goodin,et al.  Cross-sectional study assessing long-term safety of interferon-β-1b for relapsing-remitting MS , 2010, Neurology.

[70]  M. Pérez,et al.  Prevalencia de esclerosis múltiple en Ecuador , 2010 .

[71]  T. Scott,et al.  Poor recovery after the first two attacks of multiple sclerosis is associated with poor outcome five years later , 2010, Journal of the Neurological Sciences.

[72]  G. Comi,et al.  Freedom from disease activity in multiple sclerosis , 2010, Neurology.

[73]  J. Anaya,et al.  HLA class II polymorphism in Latin American patients with multiple sclerosis. , 2010, Autoimmunity reviews.

[74]  I. Koralnik,et al.  Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis , 2010, The Lancet Neurology.

[75]  Ludwig Kappos,et al.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[76]  Ludwig Kappos,et al.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[77]  R. Rudick,et al.  Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study , 2010, Multiple sclerosis.

[78]  J. Wolinsky,et al.  Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/1352458509358088 , 2022 .

[79]  N. Putzki,et al.  Efficacy of natalizumab in second line therapy of relapsing–remitting multiple sclerosis: results from a multi‐center study in German speaking countries , 2010, European journal of neurology.

[80]  S. Mousa,et al.  Disease-modifying agents in the treatment of multiple sclerosis: a review of long-term outcomes. , 2009, CNS & neurological disorders drug targets.

[81]  Yinshan Zhao,et al.  Impact of multiple sclerosis relapses on progression diminishes with time , 2009, Neurology.

[82]  David H. Miller,et al.  Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial , 2009, The Lancet Neurology.

[83]  C. Pozzilli,et al.  One‐year MRI scan predicts clinical response to interferon beta in multiple sclerosis , 2009, European journal of neurology.

[84]  F. Caceres,et al.  Early treatment of multiple sclerosis: A Latin American Experts Meeting , 2009, Multiple sclerosis.

[85]  Massimo Filippi,et al.  Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. , 2009, Archives of neurology.

[86]  J Sastre-Garriga,et al.  Measures in the first year of therapy predict the response to interferon β in MS , 2009, Multiple sclerosis.

[87]  Stephen M. Rao,et al.  Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao Brief Repeatable Neuropsychological Battery and the Minimal Assessment of Cognitive Function in MS , 2009, Multiple sclerosis.

[88]  M Rovaris,et al.  Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics? , 2009, Multiple sclerosis.

[89]  C. Polman,et al.  Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study , 2009, The Lancet Neurology.

[90]  D. Miller,et al.  Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy , 2009, Neurology.

[91]  J. Correale,et al.  Prevalence of multiple sclerosis in Buenos Aires, Argentina using the capture‐recapture method , 2009, European journal of neurology.

[92]  A. Chiò,et al.  Multiple sclerosis relapses: a multivariable analysis of residual disability determinants , 2009, Acta neurologica Scandinavica.

[93]  C. Polman,et al.  Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women , 2009, Multiple sclerosis.

[94]  C. Gorodezky,et al.  The HLA system in the prevalent Mexican Indian group: the Nahuas. , 2008, Tissue antigens.

[95]  D. B. Amos,et al.  Mysteries of the Amerindians. , 2008, Tissue antigens.

[96]  Jeffrey A. Cohen,et al.  Differential diagnosis of suspected multiple sclerosis: a consensus approach , 2008, Multiple sclerosis.

[97]  T. Dwyer,et al.  Monthly Ambient Sunlight, Infections and Relapse Rates in Multiple Sclerosis , 2008, Neuroepidemiology.

[98]  A. Kessels,et al.  Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis , 2008, Multiple sclerosis.

[99]  J. DeLuca,et al.  The relationship between cognitive deficits and everyday functional activities in multiple sclerosis. , 2008, Neuropsychology.

[100]  J. Correale,et al.  Argentine Patagonia: prevalence and clinical features of multiple sclerosis , 2008, Multiple sclerosis.

[101]  G. Koutsis,et al.  Cognitive impairment in different MS subtypes and clinically isolated syndromes , 2008, Journal of the Neurological Sciences.

[102]  F. Barkhof,et al.  POSTWITHDRAWAL REBOUND INCREASE IN T2 LESIONAL ACTIVITY IN NATALIZUMAB-TREATED MS PATIENTS , 2008, Neurology.

[103]  G. Luetic.  MS in Latin America. , 2008, International MS journal.

[104]  C. Tilbery,et al.  Immunomodulator therapy migration in relapsing remitting multiple sclerosis: a study of 152 cases. , 2008, Arquivos de neuro-psiquiatria.

[105]  Y. Fragoso,et al.  Adherence to glatiramer acetate treatment for multiple sclerosis: the Brazilian experience , 2008, Patient preference and adherence.

[106]  S. Bonissoni,et al.  Factors predicting incomplete recovery from relapses in multiple sclerosis: a prospective study , 2008, Multiple sclerosis.

[107]  À. Rovira,et al.  Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients , 2008, Multiple sclerosis.

[108]  G. Suarez-Kurtz.  Pharmacogenomics in admixed populations. , 2007, Trends in pharmacological sciences.

[109]  L. Thuler,et al.  Ethnicity‐dependent association of HLA DRB1‐DQA1‐DQB1 alleles in Brazilian multiple sclerosis patients , 2007, Acta neurologica Scandinavica.

[110]  X. Montalban,et al.  Interferon beta in secondary progressive multiple sclerosis , 2007, Journal of Neurology.

[111]  J. Correale,et al.  Association between parasite infection and immune responses in multiple sclerosis , 2007, Annals of neurology.

[112]  J. Pelletier,et al.  Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis , 2007, Multiple sclerosis.

[113]  A. Ascherio,et al.  Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. , 2006, JAMA.

[114]  J. Fleming,et al.  Multiple sclerosis and the hygiene hypothesis , 2006, Neurology.

[115]  Michael K Gould,et al.  Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. , 2006, Archives of neurology.

[116]  W. Valdar,et al.  Sex ratio of multiple sclerosis in Canada: a longitudinal study , 2006, The Lancet Neurology.

[117]  A. Melo,et al.  Clinical and epidemiological profile of multiple sclerosis in a reference center in the State of Bahia, Brazil. , 2006, Arquivos de neuro-psiquiatria.

[118]  M. Abrahamowicz,et al.  The Prognostic Value of Initial Relapses on the Evolution of Disability in Patients with Relapsing-Remitting Multiple Sclerosis , 2006, Neuroepidemiology.

[119]  F. Bethoux.  Fatigue and multiple sclerosis. , 2006, Annales de readaptation et de medecine physique : revue scientifique de la Societe francaise de reeducation fonctionnelle de readaptation et de medecine physique.

[120]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[121]  X. Montalban,et al.  Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patients , 2006, Annals of neurology.

[122]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.

[123]  G. Román,et al.  Multiple Sclerosis in Latin America , 2005, Neuroepidemiology.

[124]  D. Goodin,et al.  Response to interferon beta-1a treatment in African American multiple sclerosis patients. , 2005, Archives of neurology.

[125]  P. Sørensen,et al.  Appearance and disappearance of neutralizing antibodies during interferon-beta therapy , 2005, Neurology.

[126]  L. Kappos,et al.  Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. , 2005 .

[127]  M. Rovaris,et al.  Glatiramer acetate in multiple sclerosis , 2005, Expert review of neurotherapeutics.

[128]  D. Paty,et al.  Interferon beta-1b in secondary progressive MS , 2004, Neurology.

[129]  P. Sørensen,et al.  Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis , 2003, The Lancet.

[130]  H. Tremlett,et al.  Interrupted therapy , 2003, Neurology.

[131]  P. Cabre,et al.  Genetic and functional studies in multiple sclerosis patients from Martinique attest for a specific and direct role of the HLA-DR locus in the syndrome. , 2003, Tissue antigens.

[132]  J. Kira.  Multiple sclerosis in the Japanese population , 2003, The Lancet Neurology.

[133]  M. Horsfield,et al.  A 6‐year clinical and MRI follow‐up study of patients with relapsing–remitting multiple sclerosis treated with Interferon‐beta , 2002, European journal of neurology.

[134]  Carlos Nos,et al.  Assessment of different treatment failure criteria in a cohort of relapsing–remitting multiple sclerosis patients treated with interferon β: Implications for clinical trials , 2002, Annals of neurology.

[135]  Ralph H B Benedict,et al.  Minimal Neuropsychological Assessment of MS Patients: A Consensus Approach , 2002, The Clinical neuropsychologist.

[136]  M. Mcdermott,et al.  Quantitative functional measures in MS: What is a reliable change? , 2002, Neurology.

[137]  M. Scaff,et al.  The prevalence of multiple sclerosis in the city of São Paulo, Brazil, 1997 , 2001, Acta neurologica Scandinavica.

[138]  V. M. Rivera,et al.  Aboriginals with multiple sclerosis: HLA types and predominance of neuromyelitis optica , 2001, Neurology.

[139]  Carlo Berzuini,et al.  Predicting secondary progression in relapsing–remitting multiple sclerosis: a Bayesian analysis , 2001, Journal of the Neurological Sciences.

[140]  W. Arruda,et al.  Multiple sclerosis: report on 200 cases from Curitiba, Southern Brazil and comparison with other Brazilian series. , 2001, Arquivos de neuro-psiquiatria.

[141]  C. Poser,et al.  Diagnostic criteria for multiple sclerosis , 2001, Clinical Neurology and Neurosurgery.

[142]  J. Granados,et al.  HLA class II genotypes in Mexican Mestizos with familial and nonfamilial multiple sclerosis , 2000, Neurology.

[143]  M. F. Mendes,et al.  [Recommendations for the use of immunomodulatory drugs in multiple sclerosis: the BCTRIMS consensus] [Brazilian Committee for Treatment and Research in Multiple Sclerosis]. , 2000, Arquivos de neuro-psiquiatria.

[144]  J. Norton,et al.  The significant change for the Timed 25-Foot Walk in the Multiple Sclerosis Functional Composite , 2000, Multiple sclerosis.

[145]  J. Hillert,et al.  HLA‐DR15 is associated with lower age at onset in multiple sclerosis , 2000, Annals of neurology.

[146]  S. Reingold,et al.  The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment , 1999, Multiple sclerosis.

[147]  J. Tippin,et al.  Depressed mood in multiple sclerosis: relationship to capacity-demanding memory and attentional functioning. , 1999, Neuropsychology.

[148]  Ludwig Kappos,et al.  Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis , 1998, The Lancet.

[149]  M. Critchley.  The Journal of the Neurological Sciences , 1998, Journal of the Neurological Sciences.

[150]  J. Sotelo,et al.  Is the frequency of multiple sclerosis increasing in Mexico? , 1995, Journal of neurology, neurosurgery, and psychiatry.

[151]  O. Andersen,et al.  Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. , 1993, Brain : a journal of neurology.

[152]  Stephen M. Rao,et al.  Cognitive dysfunction in multiple sclerosis. , 1991, Neurology.

[153]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[154]  A. Beck,et al.  An inventory for measuring depression. , 1961, Archives of general psychiatry.

[155]  V. Rivera,et al.  [LACTRIMS consensus document for the pharmacological treatment of the multiple sclerosis and its clinical variants]. , 2012, Revista de neurologia.

[156]  C. Gonzalez,et al.  [Neuropsychological assessment of patients with relapsing remitting multiple sclerosis prior to the use of immunomodulatory drugs]. , 2012, Revista medica de Chile.

[157]  J. Sepulcre,et al.  [Normalisation and validation of the Brief Neuropsychological Battery as the reference neuropsychological test in multiple sclerosis]. , 2012, Revista de neurologia.

[158]  E. Cristiano,et al.  [Multiple sclerosis in Argentina. Systematic review and meta-analysis]. , 2012, Medicina.

[159]  T. Alarcón,et al.  [Prevalence of multiple sclerosis in Ecuador]. , 2010, Neurologia.

[160]  X. Montalban,et al.  [Spanish Neurology Society consensus document on the use of drugs in multiple sclerosis: escalating therapy]. , 2010, Neurologia.

[161]  A. Verma.  The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL , 2008 .

[162]  Uhc Campus.  Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study , 2005 .

[163]  A. C. Melo,et al.  Prevalence of multiple sclerosis in the city of São Paulo, Brazil, in 1990. , 1992, Neuroepidemiology.